Mainz Biomed Provides Review of 2025 Highlights
Mainz Biomed B.V. (MYNZ)
Company Research
Source: GlobeNewswire
Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectStudy Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments for the year ended December 31, 2025. The Company expects to release its year-end financial results in March 2026. Key Highlights During 2025 Colorectal Cancer Business Highlights Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company’s next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algori
Show less
Read more
Impact Snapshot
Event Time:
MYNZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYNZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYNZ alerts
High impacting Mainz Biomed B.V. news events
Weekly update
A roundup of the hottest topics
MYNZ
News
- Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingGlobeNewswire
- Mainz Biomed Provides Review of 2025 Highlights [Yahoo! Finance]Yahoo! Finance
- Mainz Biomed (NASDAQ:MYNZ) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MYNZ&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- Mainz Biomed (NASDAQ:MYNZ) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioGlobeNewswire
MYNZ
Sec Filings
- 12/30/25 - Form EFFECT
- 12/29/25 - Form 424B5
- 12/29/25 - Form 424B5
- MYNZ's page on the SEC website